Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours

BACKGROUND: Pamiparib, a PARP1/2 inhibitor, demonstrated antitumor activity in preclinical models. METHODS: This Phase 1A/1B dose-escalation/dose-expansion study enrolled adults (≥18 years) with advanced/metastatic cancer. The dose-escalation phase evaluated the recommended Phase 2 dose (RP2D), maxi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lickliter, Jason D., Voskoboynik, Mark, Mileshkin, Linda, Gan, Hui K., Kichenadasse, Ganessan, Zhang, Kathy, Zhang, Maggie, Tang, Zhiyu, Millward, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854719/
https://www.ncbi.nlm.nih.gov/pubmed/34795408
http://dx.doi.org/10.1038/s41416-021-01632-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854719/
https://www.ncbi.nlm.nih.gov/pubmed/34795408
http://dx.doi.org/10.1038/s41416-021-01632-2

Ejemplares similares